These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32953425)

  • 21. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
    Law BJ; Langley JM; Allen U; Paes B; Lee DS; Mitchell I; Sampalis J; Walti H; Robinson J; O'Brien K; Majaesic C; Caouette G; Frenette L; Le Saux N; Simmons B; Moisiuk S; Sankaran K; Ojah C; Singh AJ; Lebel MH; Bacheyie GS; Onyett H; Michaliszyn A; Manzi P; Parison D
    Pediatr Infect Dis J; 2004 Sep; 23(9):806-14. PubMed ID: 15361717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization.
    Helfrich AM; Nylund CM; Eberly MD; Eide MB; Stagliano DR
    Early Hum Dev; 2015 Sep; 91(9):541-6. PubMed ID: 26186560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.
    Winterstein AG; Choi Y; Meissner HC
    JAMA Pediatr; 2018 Feb; 172(2):154-160. PubMed ID: 29204660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
    Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
    J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.
    Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC
    Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia.
    Resch B; Liziczai K; Reiterer F; Freidl T; Haim M; Urlesberger B
    Pediatr Neonatol; 2018 Apr; 59(2):184-188. PubMed ID: 28887119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
    Winterstein AG; Knox CA; Kubilis P; Hampp C
    JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
    Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
    Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.